Blog: The rise of LGD-4033

6 November 2018

There appears to be an increasing number of athletes linked to the use of the Selective Androgen Receptor Modulator (SARM) LGD-4033.

LGD-4033, originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer, is promoted as a selective non-steroidal anabolic agent.

It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown.

It should be noted that a number of SARMs have associated health-risks, particularly for the heart and liver.

The Australian Therapeutic Goods Association (TGA) classifies LGD-4033, like all SARMs, as a Schedule 4 drug – a prescription-only medicine or animal remedy. The possession of LGD-4033 without appropriate authority is illegal.

LGD-4033 is increasingly becoming a concern – with nine Adverse Analytical Findings (AAF – positive tests) in 2017, six AAFs in 2016 and two AAFs in 2015.

Athletes are warned that not only is LGD-4033 prohibited in sport but it is not yet cleared through clinical trials.